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Abstract
Background
Previous studies have demonstrated that a number of HOX genes, a family of transcription
factors with key roles in early development, are up-regulated in head and neck squamous
cell carcinoma (HNSCC) and other cancers. The loci of several Homeobox (HOX) genes
also contain microRNAs (miRs), including miR-196a.
Methods
Global miR expression and expression of all 39 HOX genes in normal oral keratinocytes
(NOKs), oral pre-malignant (OPM) and HNSCC cells was assessed by expression microarray
and qPCR and in tissues by immunohistochemistry (IHC) and qPCR of laser microdissected
(LCM) tissues. Expression of miR196a and HOXB9 was reduced using anti-miR-196a and
siRNA, respectively. Expression microarray profiles of anti-miR196a and pre-miR196a
transfected cells were compared to parental cells in order to identify novel targets of miR-
196a. Putative miR196a targets were validated by qPCR and were confirmed as binding to
the 3’UTR of miR196a by a dual luciferase reporter assay combined with mutational analy-
sis of the miR-196a binding site.
Results
miR-196a and HOXB9 are highly expressed in HNSCC compared to NOKs, a pattern also
seen in HNSCC tissues by HOXB9 IHC and qPCR of miR-196a in LCM tissue. Knock-down
of miR-196a expression decreased HNSCC cell migration, invasion and adhesion to fibro-
nectin, but had no effect on proliferation. Furthermore, knock-down of HOXB9 expression
decreased migration, invasion and proliferation but did not alter adhesion. We identified a
novel primary mRNA transcript containing HOXB9 andmiR196a-1 as predicted from in-sil-
ico analysis. Expression array analysis identified a number of miR196a targets, including
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MAMDC2 and HOXC8. We confirmed thatMAMDC2 is a novel miR-196a target using a
dual luciferase reporter assay with the effect abolished on mutation of the binding site.
Conclusions
These results show thatmiR-196a and HOXB9 are overexpressed, perhaps co-ordinately,
as HNSCC develops and exert a pro-tumourigenic phenotype in HNSCC and OPM cells.
Introduction
The identification of a number of key molecular alterations in cancer has resulted in major ad-
vances in diagnosis and targeted therapy with validated biomarkers, heralding the advent of
personalised medicine. However, head and neck squamous cell carcinoma (HNSCC) lags be-
hind, with no consistent oncogenic drivers identified and cetuximab being the only approved
targeted therapeutic. This reflects both the molecular heterogeneity of this cancer and the pau-
city of understanding of its molecular landscape [1]. Worldwide, HNSCC presents a significant
public health problem, being the 6th most common cancer with survival rates which have not
improved significantly for several decades [2]. Hence, there is a pressing need to find both
novel targets for therapeutic intervention and new biomarkers in HNSCC.
Data mining of our published gene expression profile of normal, premalignant and HNSCC
cells (http://bioinformatics.picr.man.ac.uk/vice/PublicProjects.vice?pager.offset=15) to identify
deregulated pathways [3] has identified a number of consistently up-regulated transcription
factors in HNSCC, including several Homeobox (HOX) genes (see Hunter et al, Supplementary
data S3 and S4).HOX genes code for transcription factors with important roles in embryogene-
sis and organogenesis [4,5]. There are 39HOX genes present on chromosomes 2, 7, 12 and 17,
split into four clusters (A-D), and further sub-divided into 13 paralogous groups [4,6].HOX
proteins contain a 60 amino acid homeodomain that facilitates their binding to DNA [7].HOX
gene products interact with co-factors such as PBX, a member of the TALE family of homeodo-
main proteins, which alters their binding with DNA, regulates transcription and is needed for
specific HOX functions [8].
HOX gene expression is dysregulated in many cancers, most significantly in leukaemia. In
acute myeloid leukaemia (AML), fusion proteins of NUP98:HOXC11 and NUP98:HOXD13
have been identified which result in aberrant HOX trans-regulatory activity [9,10]. In breast
cancer, HOXA5 andHOXB13 expression is down-regulated [11,12] whereas HOXB9 is highly
up-regulated [13] and changes inHOX gene expression have been reported in lung [14,15] and
gastric cancer [16]. In HNSCC, several HOX genes show higher levels of expression in pre-ma-
lignant and cancer tissues compared to normal tissues [17]. Overall, 18HOX genes were more
highly expressed in HNSCC cells than in normal cells, among them HOXB9. However there is
a lack of clarity in the literature as to the extent and relative importance ofHOX genes in
HNSCC carcinogenesis.
HOX clusters also contain microRNAs; non-coding RNA transcripts which bind predomi-
nantly to the 3’UTR of target transcripts [18–21], resulting in translational repression or degra-
dation of the mRNA transcript [19]. MicroRNA (miR)-196 is present in three HOX clusters:
miR-196b on 7p15 (HOXA), miR-196a-1 on 17q21 (HOXB) and miR-196a-2 on 12q13
(HOXC). miR-196a-1 and miR-196a-2 have an identical mature sequence, whereas miR-196b
differs by a single nucleotide [22]. These miRNAs targetHOX genes located 5’ of their locus,
supporting the theory of posterior prevalence [21,23]. miR-196a targets several HOX genes,
HOXB9 andmiR196a in HNSCC
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including HOXA5,HOXB7, HOXB8 and HOXC8 [18,19,24,25] and has also been shown to di-
rectly target several other genes such as ANXA1, p27, KRT5, S100A9 and SPRR2C [20,26,27].
Expression of miR-196a is up-regulated in breast, gastric, lung and oesophageal cancers
[16,20,25,28], whereas it is down-regulated in melanoma [29]. miR-196a has been shown to be
up-regulated in HNSCC and may also be detected in the serum of these patients pre-operative-
ly [22,30]. In a recent meta-analysis of miR profiling in HNSCC tissues, miR196a was identi-
fied, but only in a minority of the studies assessed. Severino et al have shown that transfection
of miR196a into normal oral keratinocytes decreases proliferation, but with no effect on the ex-
pression of previously described miR196a targets [30]. Thus, the functional consequences of
miR-196a alteration in HNSCC and the protein-coding targets mediating any phenotypic
changes remain to be fully determined.
In this study, we show that miR-196a andHOXB9 are the most markedly differentially ex-
pressed miR and HOX gene respectively when comparing HNSCC and NOKs. This up-regula-
tion was also seen in head and neck cancer tissue compared to normal tissue and
bioinformatics analysis suggests that these may be co-expressed (Ensembl Transcript: RP11-
357H14.19–001). Thus, we aimed to evaluate the functional effects of high miR196a and
HOXB9 expression in HNSCC and to identify novel and direct targets of miR-196a in
this malignancy.
Materials and Methods
Cell culture and tissue samples
B16, B22, B56 (BICR56), T4 (HNSCC cell lines, Beatson Institute for Cancer Research [31,32]),
H357 (HNSCC cell line from Prof S Prime [33]), D19, D20, D4, D35 (oral pre-malignant
(OPM) cell lines, Beatson Institute for Cancer Research[34,35]), primary normal oral keratino-
cytes (NOKs; isolated as previously described [36], grown with irradiated 3T3 cells), and
OKF4 (immortalized normal oral keratinocytes; iNOK; from J Rheinwald, Boston, USA[37])
were maintained in keratinocyte growth medium (KGM) consisting of DMEM supplemented
with 23% Ham’s F-12, 10% FCS, L-glutamine (2mM), adenine (0.18mM), hydrocortisone
(0.5μg/ml) and insulin (5μg/ml) (all Sigma Aldrich, Poole, UK). CAL27 (HNSCC cell line,
ATCC) was maintained in High glucose containing DMEM supplemented with 10% FCS and
L-glutamine (2mM). All cell lines were incubated at 37°C and 5% CO2. None of the cell lines
used had a published STR profile, thus we conducted baseline STR profiling to assure no simi-
larity with any other cell line with a known profile. This was conducted immediately prior to
the experiments described below. Further information of the cells lines used in this study can
be found in S1 Table.
A tissue microarray consisting of 25 oral cavity HNSCCs was available for HOXB9 immu-
nohistochemistry. The clinicopathological details of this cohort are presented in S2 Table.
Three cores from the body of the tumour and 3 cores from the advancing edge were available
for each sample. A cohort of normal oral mucosal biopsies was used for comparison, with a site
distribution matching the HNSCC cohort. A further cohort of 16 HNSCC (S3 Table) with site
matched normal oral mucosa (from different patients) was used for the assessment of miR196a
expression in tissues.
RNA isolation and quantitative RT-PCR
Total RNA was extracted using the RNeasy mini kit (Qiagen, Manchester, UK) and quantified
using a NanoDrop Spectrophotometer (Thermo Scientific, Hemel Hempstead, UK). High ca-
pacity RNA-to-cDNA kit (Life Technologies, Paisley, UK) was used for cDNA synthesis from
total RNA. For miRNA cDNA synthesis, 10ng RNA was reverse transcribed using miRNA-
HOXB9 andmiR196a in HNSCC
PLOSONE | DOI:10.1371/journal.pone.0122285 April 10, 2015 3 / 19
specific primers. For total cDNA synthesis, 200ng RNA was reverse transcribed using random
primers. Quantitative gene expression analysis was performed using SYBR1 green or Taqman
with appropriate controls (U6 for SYBR and RNU48 (Taqman ID: 001006) for Taqman analy-
sis; hsa-miR-196a (Taqman ID: 241070)). Initial screening for all HOX genes was by SYBR
green qPCR on a Stratagene platform MX3005p (primers sequences in S4 Table) [14]. Addi-
tional qPCR was performed using an ABI 7900HT (Life Technologies, Paisley, UK) and the rel-
ative expression of genes, normalised to the abundance of the relevant control transcript, was
calculated using RQManager 1.2.1 (Life Technologies, Paisley, UK).
Affymetrix miRNA array
RNA from duplicate cultures of NOK (normal OKs), Cal27 and BICR56 (both HNSCC) ex-
tracted using the mirVana miRNA isolation kit (Life Technologies, Paisley, UK) and was then
prepared as per the manufacturer’s protocols (http://media.affymetrix.com/support/
downloads/manuals/ flashtag_user_guide.pdf) prior to hybridisation onto the Affymetrix Gen-
eChip miRNA 1.0 Array. The array data was normalised using RMA (RMAEXpress) and then
loaded into tMeV (Craig Venter Institute, Rockville, CA) and analysed using the statistical
analysis of microarray tool (SAM) with a false discovery rate<1% and fold change of>5, com-
paring NOK with HNSCC. The primary data is available in the NCBI GEO database (accession
number GSE52811).
HOXB9-miR-196a-1 primary transcript
To investigate the presence of a common HOXB9-miR-196a-1 primary transcript (PT), prim-
ers were designed that spanned the 6.3Kb between HOXB9 exon1 and miR-196a-1 precursor
transcript (forward: 5’ AATTAGGTAGTTTCATGTTGTTGGGCC 3’; reverse: 5’ ATAA
TAGCTGCTAAGCGTCCC AGAAAT 3’). For the reverse transcription step, primary tran-
script primers were used with M-MLV reverse transcriptase (Promega, Southampton, UK), fol-
lowed by PCR using the same primers (product 6.3kB). Nested primers were designed to give a
295bp product within this transcript (forward: 5’ AAAGTCAGGGCAGGAGAGGGAAGGG
GAA 3’, reverse: 5’ CAATTTGCCAGCCCTATGAAGTCTGCT 3’), with RNaseA treated
(RNA was incubated for 1 hour at 37°C with 100μg/ml RNaseA (Promega, Southampton, UK)
and no-reverse transcriptase (RT) controls. The PCR products were separated on a 2% (w/v)
agarose gel, visualised under UV transillumination and purified using gel extraction kit (Bio-
line, London, UK). This product was then cloned into TOPO TA Cloning vector (Life Technol-
ogies, Paisley, UK) and positive colonies were selected using blue/white screening, purified
using Isolate plasmid mini kit (Bioline, London, UK) and sequenced.
Laser Capture Microdissection (LCM)
Fresh 4μM sections of formalin-fixed, paraffin-embedded (FFPE) tumour and normal tissue
(as described above) were de-waxed, stained with haematoxylin and dehydrated by xylene.
LCM was carried out using a Pixcell II LCM system (Arcturus, Life Technologies, Paisley, UK).
RNAqueous1Micro kit (Life Technologies, Paisley, UK) was used to extract RNA from the
cells, according to the manufacturer’s instructions.
Protein extraction and western blotting
RIPA buffer (Sigma Aldrich, Poole, UK) containing protease and phosphatase inhibitors
(Roche, West Sussex, UK) was added to the cell pellet on ice and then centrifuged at
13,000rpm for 5 min at 4°C. The protein was quantified using BCA method [38] as per
HOXB9 andmiR196a in HNSCC
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manufacturer’s protocol (Thermo Scientific, Hemel Hempstead, UK). 40 μg of total protein
was loaded onto a 12% (v/v) SDS-PAGE gel. Wet transfer for 1h at 30V transferred protein to a
nitrocellulose membrane, before incubation for 1h in blocking buffer (5% (w/v) dried milk
with 3% (w/v) BSA in tris buffered saline containing 0.05% (v/v) tween-20) and incubation
overnight at 4°C with the primary monoclonal antibody anti-HOXB9 (1:500 in blocking buffer,
Abcam, Cambridge, UK) or anti-β-actin (1:3,000 in blocking buffer, Sigma Aldrich, Poole,
UK). The membrane was then incubated in horseradish peroxidase-conjugated anti-rabbit IgG
(1:3000 in blocking buffer) for 1h and developed with SuperSignal West Pico chemilumines-
cent substrate (Thermo Scientific, Hemel Hempstead, UK).
Immunohistochemistry (IHC)
Antigen retrieval was performed using a pressure cooker [39] on sections followed by incuba-
tion with anti-HOXB9 (1: 400, Sigma Aldrich, Poole, UK) overnight at 4°C. Vectastain Elite
ABC rabbit IgG kit (Vector Laboratories Inc. Burlingame, CA, USA) was used for secondary
antibody (30min at room temperature), followed by colour development by DAB reagent (Vec-
tor Laboratories Inc. Burlingame, CA, USA). Submandibular salivary gland and sections with
no primary antibody were used as positive and negative controls respectively. IHC was ana-
lysed by the semi-quantitative modified Quickscore method on 6 cores from each tumour [40].
Anti-miR and siRNA transfection
B16, D19 or OKF4 cells were seeded in a 6-well plate and incubated overnight. Keratinocytes
were transfected when 50–70% confluent with anti-miR-196a or pre-miR-196a (50nM, Life
Technologies, Paisley, UK) or siRNA targeting human HOXB9 (50nM, Sigma Aldrich, Poole,
UK) using Oligofectamine (Life Technologies, Paisley, UK) according to the manufacturer’s
protocol. A random, non-targeting negative control sequence (Life Technologies, Paisley, UK)
was used in all experiments. Cells were transfected and incubated for 48h in DMEM supple-
mented with 20% FCS before being used for the functional assays.
Proliferation Assay
Cells were seeded in a 96-well plate (Corning Inc, Corning, NY, USA) in triplicate for each
time point (0, 24, 48, 72 and 96h) at a density of 5x103 cells in DMEMmedia supplemented
with 10% (v/v) FCS. MTS reagent (Promega, Southampton, UK) was added to the wells, incu-
bated for 1h and then read at 490nm on a Tecan Infinite M200 spectrophotometer (Tecan,
Männedorf, Switzerland) using Magellan software.
Adhesion Assay
A 96-well plate was coated with 0.1% (w/v) fibronectin (Sigma Aldrich, Poole, UK) in PBS
(1:100) and incubated overnight at 4°C. The following day wells were washed with PBS and
incubated with DMEM containing 1% (w/v) BSA for an hour. The transfected cells were
plated in triplicate at a density of 3x104 cells/well in DMEM and incubated for 1h. Non-adher-
ent cells were removed by washing with PBS. MTS reagent (Promega, Southampton, UK)
was added to the wells, incubated for 1h and then read at 490nm on a Tecan Infinite M200
spectrophotometer.
Transwell Migration and Invasion Assay
To assess migration, transfected cells (8x104) in DMEM with 0.1% (w/v) BSA were placed, in
duplicate, in the top chamber of a 24-well transwell insert (8μM pore size; BD Biosciences,
HOXB9 andmiR196a in HNSCC
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Oxford, UK). The bottom of the 24-well plate was filled with DMEM supplemented with 2%
(v/v) FCS and the cells incubated overnight at 37°C. For invasion assays the top chamber of a
transwell insert was covered with 100μL of growth factor reduced matrigel (BD Biosciences,
Oxford, UK) and incubated overnight at 37°C. 8x104 transfected cells in 0.1% (w/v) BSA in
DMEM were placed in the top chamber in duplicate. DMEM containing 2% (v/v) FCS was
placed in the bottom of the 24-well plate followed by 48h incubation at 37°C. Mitomycin C
(1μg/mL) was added to the medium in both chambers. For both assays the migrating or invad-
ing cells present on the underside of the transwell insert were stained with crystal violet and
then counted at four random fields by light microscopy.
Agilent Gene expression microarray
The quality of total RNA was assessed using an Agilent Bioanalyzer, (Agilent, Wokingham,
UK) with QC thresholds 28s:18s2:1 and RIN = 10. Biological triplicates of B16 and D19
cells were transfected with anti-miR-196a and negative control, whereas OKF4 cells were trans-
fected with pre-miR-196a and negative control in duplicate (total 16 samples). Samples were
prepared and hybridised to Agilent oligonucleotide microarray chips (Sureprint G3; Agilent,
Wokingham, UK) according to the manufacturer’s protocol (http://www.chem.agilent.com/
library/usermanuals/public/g4140-90041_one-color_tecan.pdf). Data was loaded into Qlucore
Omics Explorer (Qlucore AB, Lund, Sweden) and, following normalisation and principle com-
ponent analysis, T-test (p<0.01, with multiple test correction) was used to compare the trans-
fected with the parental cells for each cell line. The top 50 up- and down-regulated genes were
selected for further validation by qPCR. The primary data is available in the NCBI GEO data-
base (accession number GSE52810).
Luciferase reporter assay and site directed mutagenesis
TheMAMDC2 3’UTR was amplified using cDNA from B16 cells (primers: wt forward 5’ AAA
AAAAAA CGCGTAAATGATCTGCATTGGATTTACT 3’ and wt reverse 5’ AAAAAAAA
GTTTAAACAAGATTTT CAAATTATTTTTATTAGGTAATTTTATAATTTC 3’ containing
MluI and PmeI restriction sites, respectively). The amplified PCR product was ligated into
pMIR-REPORT (Ambion). The miR-196a binding site within theMAMDC2 3’UTR was mu-
tated using PCR-based site-directed mutagenesis. pMIR REPORT cloned with wt 3’UTR was
used as the template in the PCR. The primers used for mutation of the miR-196a binding site
had Tm of> = 78°C (MAMDC2mutant forward: 5’ CCTTCTTTA TTCCCCCTTTGAGA
CGCTTTTGAAGTCACTATAGC 3’ and MAMDC2 mutant reverse: 5’ GCTCAT AGTGA
TTCAAAAGCGTCTCAAAGGGGGAATAAAGAAGG 3’, mutated bases in bold). The
PCR product was incubated for 1h with DpnI (New England Biolabs, Herts, UK) to degrade
methylated template plasmid. 500 ng of pMIR vector (wt or mutant) was transfected into B16
HNSCC cells with 50 ng of pRL-TK Renilla luciferase vector (Promega, Southampton, UK)
and pre-miR-196a or scrambled negative control (50nM) (Life Technologies, Paisley, UK)
using Fugene HD transfection reagent (Promega, Southampton, UK). The cells were incubated
for 48h and then the luciferase activity for firefly and renilla was measured using dual luciferase
reporter assay (DLRA) (Promega, Southampton, UK) according to the manufacturer’s proto-
col. The assay was repeated thrice in triplicate.
Statistical Analysis
Non-parametric Mann-Whitney U test was performed on the IHC tissue sample scoring for
HOXB9 and the absolute value of the qPCR performed on LCM tissue sample for miR-196a.
HOXB9 andmiR196a in HNSCC
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Parametric student’s t-test was used to calculate all other significance values. Results were only
considered significant if p<0.05.
Ethics Approval
Ethics approval for the use of biopsy tissues in this study was obtained from The West Glasgow
LREC (ref: 08/S0709/70). Ethical approval for the normal oral keratinocyte primary cultures
used was obtained from the National Research Ethics Service, UK: 09/H1308/66 and human
tissue was used with written, informed consent. The Ethics Approval waived the need for spe-
cific consent in both cases as the material to be used was anonymised and surplus to diagnostic
requirements.
Results
miRNAmicroarray analysis reveals high miR-196a expression in
HNSCC-derived cell line
MicroRNA profiling using the Affymetrix miRNA array identified a number of significantly
differentially expressed miRs between the NOKs and HNSCC cells (Fig 1A). As the number of
samples was small the stringency applied in analysis was high (FDR<1%), in order to robustly
identify differentially expressed miRs for further analysis. The number of hits was further limit-
ed to those that changed5 fold, finally identifying miR-196a, miR-34a and miR-708, as being
differentially expressed (Fig 1B). Of these, only miR-196a was highly expressed in HNSCC.
Validation of miR-196a expression by qPCR in a full panel of NOK, OPM and HNSCC cells
showed high expression in all HNSCC cells tested with variable expression in OPM cells, two
Fig 1. miR-196a is up-regulated in OPM and HNSCC-derived cell lines. 1A:Heat map showing
differentially expressed microRNAs in microarray data from Affymetrix miRNA array on comparison of
HNSCC and NOK using SAMwith a FDR of 1%. BICR56 and CAL27 are HNSCC cells and NOKs are normal
oral keratinocytes. The values presented are the mean of 2 technical replicates. 1B. Candidate miRs were
selected as differentially expressed with a FDR of 1% and fold change5. 1C. Expression of miR-196a in a
panel of NOK, OPM and HNSCC cells. * p<0.05, ** p<0.01.
doi:10.1371/journal.pone.0122285.g001
HOXB9 andmiR196a in HNSCC
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of which had similar expression to that seen in the HNSCCs (Fig 1C). Expression in NOKs was
consistently low.
HOXB9 is the most highly expressed of a number of HOX genes
elevated in HNSCC-derived cell lines
Expression analysis of all 39HOX genes revealed that all were more highly expressed in
HNSCC compared to NOK (Fig 2A and S2 Fig). The highest differential expression seen was of
HOXA4 (291 fold, p<0.01), HOXA5 (105 fold, p<0.01),HOXA9 (155 fold, p<0.001), HOXB9
(1293 fold, p<0.001), HOXC9 (41 fold, p<0.01) and HOXD10 (23 fold, p<0.01), all of which
are well recognised in the literature [7,17,41,42], but there was marked variability in the extent
of the fold change. HOXB9 was the most markedly differentially expressed, on average>
1000-fold higher than in NOK. This was validated by qPCR, which demonstrated consistently
high gene expression of HOXB9 in OPM and HNSCC cells (Fig 2B). Despite a lack of direct
correspondence in HOXB9 protein levels (particularly for B16), the difference in expression
Fig 2. HOXB9 is over-expressed in OPM and HNSCC-derived cell lines. 2A.Overall mean expression of all 39HOX genes as measured by qPCR in a
panel of normal oral keratinocytes and oral cancer cells, relative to the internal endogenous control β-actin. In general, there is increased expression of most
HOX genes, but particularly A4, A10, B9 and D10. 2B. Expression of HOXB9 in a panel of NOK, OPM and HNSCC cells. 2C. Expression of HOXB9 protein
assayed byWestern blotting for NOK cells compared to HNSCC (upper panel) and OPL (lower panel). * p<0.05, ** p<0.01, *** p<0.001.
doi:10.1371/journal.pone.0122285.g002
HOXB9 andmiR196a in HNSCC
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was also seen in Western blot, with the HNSCCs and OPMs expressing more HOXB9 protein
than NOK, (Fig 2C).
miR-196a and HOXB9 are more highly expressed in HNSCC tissues
than in normal oral mucosa
The expression of miR-196a in tissues was assessed by qPCR of RNA extracted from laser-cap-
tured FFPE tissue. Whilst RNA from FFPE tissues is often degraded, the small size of micro-
RNAs allows efficient recovery from fixed tissue [43]. Significantly higher expression of miR-
196a was observed in 16 HNSCC tissues when compared to 16 unmatched normal mucosa
(Fig 3A, p<0.05), with some variation in expression seen in the normal samples. Analysis of
HOXB9 expression by immunohistochemistry in a TMA containing 25 HNSCC samples com-
pared with 10 normal oral mucosa samples revealed that this protein was more highly express-
ed in HNSCC compared to normal samples, as assessed by the Quickscore method (Fig 3B and
3C, p<0.001). In normal tissues, expression of HOXB9 was expressed at low levels, confined to
the nuclei of the basal and spinous layers (Fig 3C Panel 1 and 2), whilst in HNSCC the nuclear
intensity increased, with a greater proportion of cells in tumour nests expressing HOXB9
Fig 3. miR-196a andHOXB9 are up-regulated in HNSCC tissue samples. 3A-C. Expression of miR-196a
(3A) andHOXB9 in tissues (3B, 3C) measured by qPCR of LCM tissues and immunohistochemistry,
respectively. Representative photomicrographs show HOXB9 expression in normal tissue (C panels 1 and 2)
and HNSCC (C panels 3 and 4). The HOXB9 expression in tissue was semi-quantitatively assessed using
the Quickscore method. The pattern of expression correlates with in-vitro data and both are up-
regulated in cancer tissue, albeit the fold change is less (3.4 fold for miR-196a). * p<0.05, ***p<0.001.
Photomicrographs overall magnification x200, scale bar = 200μm. 3D.miR-196a-1 andHOXB9 are co-
expressed on same novel primary transcript DNA agarose gel electrophoresis showing presence of 295 bp
transcript after nested PCR. The transcript is present in B16 cell line and at the expected size. (-) RT: without
reverse transcriptase control, (+) RNaseA: RNA treated with RNaseA at 37°C for 1 hour before cDNA
production.
doi:10.1371/journal.pone.0122285.g003
HOXB9 andmiR196a in HNSCC
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(Fig 3C Panel 3 and 4). Furthermore, in the HNSCC tissues, there was cytoplasmic expression
ofHOXB9 in many cells.
HOXB9 and miR-196a-1 are co-transcribed on the same novel primary
transcript
HOXB9 and miR-196a-1 are spatially closely related on Chr17. To show that HOXB9 and miR-
196a-1 are co-transcribed on same primary transcript, primers were designed which spanned
between HOXB9 exon 1 to miR-196a-1 precursor transcript (6.3 Kb). Nested primers were de-
signed which amplified a 295bp region within this 6.3 Kb transcript (S1 Fig). A product of the
expected molecular size was obtained (Fig 3D); no products were observed in the absence of re-
verse transcriptase (-RT) or following prolonged incubation with RNase A, suggesting this
product is derived from aHOXB9-miR-196a-1 polycistronic primary transcript, rather than
from genomic DNA contamination.
HOXB9 and miR-196a increase HNSCC cell migration and invasion
Given that both HOXB9 and miR-196a are highly expressed in HNSCC we assessed the pheno-
typic consequences of this in OPM and HNSCC cells, particularly assessing features that pro-
mote the ability of the cells to proliferate and to spread, enhancing the development of the
tumour. Reducing expression of miR-196a orHOXB9 by anti-miR-196a (95% (B16) and 92%
(D19)) and HOXB9 siRNA (62% (B16) and 48% (D19)), respectively (Figs 4A and 5A), re-
duced the ability of the OPM and HNSCC cells to migrate and invade into Matrigel (Figs 4C,
4D, 5C and 5D). The effects on proliferation and adhesion to fibronectin, a major component
Fig 4. Functional effects of anti-miR-196a in HNSCC-derived cell lines. 4A. B16 and D19 cells were
transfected with anti-miR-196a and negative control resulting in 95% and 92% reduction in miR-196a
expression respectively compared to negative control. 4B-E. Anti-miR-196a decreases adhesion to
fibronectin (B; in B16 only), migration (C), invasion (D) but has no effect on proliferation (E) in HNSCC cells.
* p<0.05, *** p<0.001. All experiments were conducted in duplicate and completed three times.
doi:10.1371/journal.pone.0122285.g004
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of the extracellular matrix, were more variable as reducing miR-196a expression reduced adhe-
sion in HNSCC cells but not OPM cells, with no effect on proliferation in either cell type (Fig
4B and 4E). Supporting these observations, increased migration was seen after transfection of
OKF4 (immortalised NOK) with pre-miR-196a, whilst there was no effect on proliferation or
adhesion (data not shown). ReducingHOXB9 expression by siRNA additionally reduced pro-
liferation of OPM and HNSCC cells (Fig 5E). Adhesion to fibronectin was significantly in-
creased in B16 only, but only to a small degree (Fig 5B).
Expression microarray analysis identifies known and putative miR-196a
targets
Expression array data from both anti-miR (B16 and D19) and pre-miR (OKF4) transfected
cells were used to identify consistent changes in gene expression related to alterations in miR-
196a expression. This approach identified 353 altered genes (p<0.01 by t-test) with the top 50
up- and down-regulated shown in Fig 6A. Gene Ontology (GO) enrichment analysis using
DAVID (http://david.abcc.ncifcrf.gov) demonstrated a number of over-represented GO bio-
logical processes, including amine/amino acid transport, DNA repair and regulation of tran-
scription (S5 Table). From this list, the top 20 up-regulated genes underwent further in-silico
analysis for predicted miR-196a binding to the 3’UTR of each gene, to further focus the list to
potential direct targets of miR-196a (Fig 6B). Other than HOXC8 (S3D Fig), which has already
been demonstrated to be a target of miR196a [18], the gene with the highest predicted interac-
tion with miR-196a was MAMDomain Containing 2 (MAMDC2), which showed a good
match based on sequence complementarity, energy of binding and evolutionary conservation
Fig 5. Functional effects of HOXB9 siRNA in HNSCC-derived cell lines. 5A. B16 and D19 cells were
transfected withHOXB9 siRNA and negative control. There was 62% and 48% down-regulation seen in
HOXB9 expression compared to negative control in B16 and D19 respectively. 5B-E.HOXB9 siRNA
decreases migration (C), invasion (D) and proliferation (E) with no consistent change in adhesion to
fibronectin (B) in HNSCC cells. *p<0.05, **p<0.01, ***p<0.001. All experiments were conducted in
duplicate and completed three times.
doi:10.1371/journal.pone.0122285.g005
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of the site of 3’UTR to miR-196a (www.microrna.org). qPCR analysis of a number of reported
miR196a targets in other cancers, KRT5, ANXA1, S100A9 andHOXC8, was conducted (S2 Fig)
[20,27]. These showed no consistent change on knockdown of miR196a in HNSCC and OPM
cells, although HOXC8 was differentially expressed in anti-miR196a transfected D19 cells.
MAMDC2 is a novel direct target of miR-196a
The change inMAMDC2 expression seen on manipulation of miR-196a expression was vali-
dated by qPCR in the cells used in the microarray (Fig 6C). This confirmed the microarray
data, showingMAMDC2 expression increased after anti-miR-196a transfection in OPM
(p<0.01) and HNSCC (p = 0.08) cells and was reduced after pre-miR-196a transfection into
immortalised NOK (p<0.05). miR-196a over-expression significantly suppressed luciferase ac-
tivity from a wild-typeMAMDC2 3’UTR reporter construct in B16 cells (Fig 6D). This sup-
pression was not observed following mutation of the predicted miR-196a binding site (Fig 6D),
indicating a direct effect of miR-196a onMAMDC2 expression at a transcript level.
Fig 6. Prediction of putative targets of miR-196a in HNSCC-derived cell lines. 6A.Microarray Heat Map
depicting top 50 miR-196a up-regulated and down-regulated genes. Yellow samples were compared against
blue samples (high and low miR-196a expression respectively) using Qlucore Omics Explorer with T-test,
p<0.01. Yellow box consists of B16 negative control, D19 negative control and OKF4 pre-miR-196a
transfected cells whereas blue box consists of B16 anti-miR-196a, D19 anti-miR-196a and OKF4 negative
control transfected cells. 6B. Table depicting top 20 up-regulated putative targets based on expression
analysis and miRwalk analysis of potential miRNA targets. It also shows number of miR-196a binding sites
present in 3’UTR of the gene (www.microRNA.org) 6C: The changes inMAMDC2 expression on transfection
of anti-miR-196a were validated by qPCR in samples used in microarray. 6D: pMIR-REPORT luciferase
vector was cloned with wild-typeMAMDC2 3’UTR (wt) and the predicted miR-196a site in the 3’UTR was
mutated by site-directed mutagenesis (mutated). These were co-transfected with negative control or pre-miR-
196a, pRL-TK renilla luciferase control vector into B16 (HNSCC cells). The relative luminescence value
(firefly/renilla value) of wt/pre-miR-196a was significantly lower than wt/negative control, with no significant
difference in the mutated 3’UTR. *p<0.05, **p<0.01, ***p<0.001.
doi:10.1371/journal.pone.0122285.g006
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Discussion
There is now considerable evidence that miR-196a and HOXB9 exert a pro-tumorigenic influ-
ence in many cancers [13,15,22,27]. Our data convincingly demonstrate high expression of
both miR-196a andHOXB9 in HNSCC and in at least a subset of OPMs. This is in keeping
with recent studies in HNSCC and also a number of other cancers, including breast and non-
small cell lung carcinoma (NSCLC) [5,7,22,28,30,44]. Furthermore, a key role for miR-196a
polymorphisms has emerged in relation to cancer risk, conferring increased susceptibility to a
number of cancers, particularly in Asian populations [45]. Despite a well-recognised role in in-
vasive disease, the function of miR-196a overexpression in the pre-invasive stage of HNSCC
development has not been investigated before. We found high miR-196a expression in some
OPM samples, whilst in others the level of expression is similar to NOK. Further investigations
will be required to define the role of this overexpression and whether OPMs with high miR-
196a expression progress to HNSCC.
Recent investigations in oral carcinomas have also demonstrated a pro-tumorigenic pheno-
type in cells expressing high levels of miR-196a, and this has been linked to poor patient out-
come, with similar effects seen in NSCLC and gastric cancer [16,25]. Liu et al showed
overexpression of miR-196a in HNSCC cells had little effect on tumour cell proliferation, but
did result in an increase in cell migration [22], which is in keeping with our findings and also
those seen on manipulation of miR-196a expression in a number of other cancer cell types
[46]. Conversely, overexpression of miR-196a in NOKs resulted in a marked reduction in pro-
liferation [30], but it is difficult to directly compare these effects with those seen in HNSCC
cells given the markedly different genomic and transcriptomic background. Our investigations
of transfection of pre-miR-196a into the immortalised NOK cell line OKF4 showed no change
in proliferation and a small increase in migration (data not shown).
HOXB9 expression is elevated in a range of cancers including breast, NSCLC and hepatocel-
lular carcinoma [5,7,47], but decreased expression has been related to poor prognosis in others
[48]. The increased expression of HOXB9 in HNSCC which we have demonstrated in vitro and
in tissues has also been shown in a small number of other microarray analyses and in compara-
ble qPCR assessment of HOX gene expression in HNSCC [17,49,50]. The identification of the
differential expression of HOXB9 in HNSCC in the array analysis of Ginos et al [49] is notable
asHOXB9 was not identified in the original Hunter et al dataset [3], but was shown in this
study by qPCR (Fig 2). This illustrates the limitations of many expression array analyses given
the variability of samples analysed and uncertainties surrounding the probesets which have
been used to detect the targets. For the first time we have demonstrated increasedHOXB9 ex-
pression in OPM cultures, which was not seen in the investigation of Hassan et al [17]. Howev-
er, 3 of the 4 cultures we used were derived from severely dysplastic lesions which progressed
to HNSCC in less than 6 months (D19, D20 and D35). This indicates that a more detailed anal-
ysis of the expression and role of HOXB9 in OPM is warranted to determine if expression of
HOXB9 increases with OPM severity.
We have shown thatHOXB9 enhances migration, invasion and proliferation of both
HNSCC and OPM cells in keeping with the effects of highHOXB9 expression in other cancers,
but which has not been demonstrated previously in HNSCC or in pre-invasive disease. Our
findings are in keeping with the observed increase in migration and invasion in breast cancer,
where elevated HOXB9 expression enhances the DNA damage response, not only conferring
resistance to ionizing radiation, but also associated with induction of epithelial to mesenchymal
transition (EMT) [51]. Investigations in other cancers have demonstrated similar roles in addi-
tion to enhancement of tumour proliferation and angiogenesis [13,52]. These are important
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issues to address in relation to both miR196a and HOXB9 and we are currently undertaking
further investigation of the mechanisms of altered migration and invasion.
The apparent similarity in the patterns of expression ofHOXB9 and miR-196a has been
demonstrated in Hodgkin lymphoma and AML cells, suggesting co-regulation, but in neither
case were further investigations conducted [53,54]. The presence of numerous polycistronic
transcripts from theHOX loci has been inferred from analysis of high resolution transcription-
al profiling, including a putative transcript which includesHOXB7, HOXB8, HOXB9 and
miR-196a-1 [55]. This transcript is annotated in Ensembl (Transcript: RP11-357H14.19–001),
without direct experimental evidence of its existence. We have demonstrated the existence of a
transcript that at least spans the 6.3kb region between the open reading frames ofHOXB9 and
miR-196a-1. However, what is not clear is what proportion ofHOXB9 and miR-196a expres-
sion is accounted for by this transcript. Given that the expression of HOXB9 and miR-196a is
not completely coordinated, particularly in OPM cells (Figs 2B and 1C), it is likely that this
transcript only contributes a proportion of the pool of processed mRNA for HOXB9 and miR-
196a, indicating that, whilst there may be co-expression, expression of HOXB9 and miR-196a
is under the control of other factors, which remain to be elucidated, which are responsible for
different transcripts. An understanding of the primary transcripts used in the expression of
bothHOXB9 and miR-196a will be important in directing possible approaches to inhibition.
There are significant difficulties in the identification of endogenous miRNA targets and this
has led to the use of a wide range of techniques, ranging from in-silicomethods to direct assess-
ment of binding between the miRNA seed sequence and binding site in the 3’UTR of cognate
mRNAs. We decided to pursue novel targets of miR-196a by expression microarray following
miR-196a over-expression and knockdown, despite the acknowledged limitations of this ap-
proach, including possible effects on protein and not mRNA. The microarray expression data
and subsequent in-silico analysis identified a number of potential targets of miR-196a, includ-
ing some which have been identified in other cell types, such asHOXC8 (S3 Fig) [18]. However,
the overall GO enrichment analysis only identified a small number of enriched biological pro-
cesses that were affected by manipulation of miR-196a expression. The most enriched catego-
ries included DNA repair, the DNA damage response and various transporter pathways (S1
Table). These do not appear to map directly to the observed phenotype, which may be partly
due to the relatively small number of differentially expressed genes identified and also demon-
strate the interaction of miR-196a in a controlling a wide range of different processes in the
cell. Interestingly, we observed no consistent changes in the expression of miR-196a targets
which have been identified in other cancer types. This may indicate a level of tumour specificity
in the actions of miR-196a.
Overall, the highest ranked novel gene target in our analysis was MAMDC2. The level of
MAMDC2 expression varies between the NOK, OPM and HNSCC cells, indicative of control
of expression by other, as yet unknown mechanisms. However, given the effect on transfection
of pre-miR196 or anti-miR196 presented in Fig 6C and 6D, there is good evidence that
MAMDC2 is under the direct control of miR196a. MAMDC2 is a transmembrane cell adhe-
sion protein of the immunoglobulin superfamily. MAM (meprin/A5-protein/PTPmu) do-
mains are present in numerous proteins with varied functions, with many associated with
promotion of cell-cell adhesion [56,57]. Correspondingly, mutations in the MAM domain of
the receptor protein tyrosine phosphatase T have been shown to promote cancer cell migration
and metastasis in colorectal cancer [58,59]. Whilst this would be in keeping with the phenotype
observed upon transfection with anti-miR-196a, this requires further investigation to establish
if this observation can be attributed to the biological functions of MAMDC2. Given that a
number of small molecules which interfere with cell adhesion are currently being tested as anti-
cancer agents, this may also represent a novel therapeutic target.
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Given that elevatedHOXB9 expression and high serum levels of miR-196a have been associ-
ated with poor prognosis and recurrence in other tumour types [5,7,16], it is conceivable, that
together, they may be of prognostic use in HNSCC. Potential therapeutic applications may be
more challenging as, whilst inhibitors of theHOX-PBX interaction are available and effective
[8], some of the 5’ HOX genes (e.g. HOXD10 and HOXB9) are less PBX dependent which may
limit their use [60], thus new strategies for disruption of this interaction may prove more effec-
tive. Furthermore, if the molecular mechanisms responsible for the transcription of the novel
primary transcript identified here can be elucidated, it may be possible to inhibit its expression
and subsequent effects.
Conclusions
In this manuscript we have demonstrated that both HOXB9 and miR196a are highly expressed
in HNSCC both in vivo and in vitro. Both exert a pro-tumour phenotype and we have demon-
strated a putative primary transcript which bears both coding sequences. This suggests that
inhibition of expression of genes across this locus may prove a useful therapeutic strategy
as this will inhibit a number of pro-tumorigenic factors. Furthermore we have identified
MAMDC2 as a novel target of miR196a in HNSCC, suggesting further interrogation of the bio-
logical significance of the miR-196a/MAMDC2 axis may enhance understanding of HNSCC
pathogenesis.
Supporting Information
S1 Fig. Schematic diagram of the putative primary transcript and the length of the PCR
product for both the primers utilised in the nested PCR analysis.
(TIF)
S2 Fig. Expression of all HOX genes analysed by qPCR, showing data in the full panel of
cell cultures tested, including normal (black), OPM (red) and HNSCC (blue), arranged by
group (A-D) and in numerical order.
(TIF)
S3 Fig. Expression of putative miR196a targets suggested form investigation in other can-
cers, as assessed by qPCR in anti-miR196a transfected D19 and B16 cells, and pre-miR
196a transfected OKF4 cells in panel D. A: Keratin V; B: Anexin A1; C S100A9;D: HOXC8.
Only HOXC8 shows significant changes in expression and this only in D19 (p<0.01). The data
does not support regulation of KRT5, ANXA1 or S100A9 by miR196a in HNSCC.
(TIF)
S1 Table. Clinical details of the HNSCC and OPM cell lines used in this study. All cell lines
are HPV negative.
(DOCX)
S2 Table. Clinical and pathological details of the 25 HNSCC samples in the TMA used for
HOXB9 IHC. FOM = Floor of mouth, RM = retromolar, BM = buccal mucosa.
(DOCX)
S3 Table. Clinical pathological details of HNSCC samples used for Laser capture microdis-
section FOM = Floor of mouth, RM = retromolar, BM = buccal mucosa.
(DOCX)
S4 Table. A full list of qPCR primers used in this study.
(DOCX)
HOXB9 andmiR196a in HNSCC
PLOSONE | DOI:10.1371/journal.pone.0122285 April 10, 2015 15 / 19
S5 Table. Gene ontology enrichment analysis demonstrating significantly enriched GO bio-
logical processes on manipulation of miR-196a expression. The total number of significantly
differentially expressed genes entered into this analysis was 353. Analysis generated by analysis
of the gene list in DAVID (http://david.abcc.ncifcrf.gov).
(DOCX)
Author Contributions
Conceived and designed the experiments: LD FH RM CMDWL KDH. Performed the experi-
ments: LD FH. Analyzed the data: LD FH RM CMDWL KDH. Contributed reagents/materi-
als/analysis tools: CR CM DWL KDH. Wrote the paper: LD FH RM CMDWL KDH.
References
1. Markovic A, Chung CH (2012) Current role of EGF receptor monoclonal antibodies and tyrosine kinase
inhibitors in the management of head and neck squamous cell carcinoma. Expert Rev Anticancer Ther
12: 1149–1159. doi: 10.1586/era.12.91 PMID: 23098115
2. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer.
Nat Rev Cancer 11: 9–22. doi: 10.1038/nrc2982 PMID: 21160525
3. Hunter KD, Thurlow JK, Fleming J, Drake PJ, Vass JK, et al. (2006) Divergent routes to oral cancer.
Cancer Res 66: 7405–7413. PMID: 16885335
4. Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL, et al. (2005) The pathophysiology
of HOX genes and their role in cancer. J Pathol 205: 154–171. PMID: 15643670
5. Calvo R, West J, Franklin W, Erickson P, Bemis L, et al. (2000) Altered HOX andWNT7A expression in
human lung cancer. Proc Natl Acad Sci U S A 97: 12776–12781. PMID: 11070089
6. Barber BA, Rastegar M (2010) Epigenetic control of Hox genes during neurogenesis, development,
and disease. Ann Anat 192: 261–274. doi: 10.1016/j.aanat.2010.07.009 PMID: 20739155
7. Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, et al. (2010) HOXB9, a gene overex-
pressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A 107:
1100–1105. doi: 10.1073/pnas.0912710107 PMID: 20080567
8. Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS (2010) Targeting HOX and PBX tran-
scription factors in ovarian cancer. BMC Cancer 10: 89. doi: 10.1186/1471-2407-10-89 PMID:
20219106
9. Taketani T, Taki T, Shibuya N, Kikuchi A, Hanada R, et al. (2002) Novel NUP98-HOXC11 fusion gene
resulted from a chromosomal break within exon 1 of HOXC11 in acute myeloid leukemia with t(11;12)
(p15;q13). Cancer Res 62: 4571–4574. PMID: 12183408
10. Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, et al. (1998) NUP98-HOXD13 gene
fusion in therapy-related acute myelogenous leukemia. Cancer Res 58: 4269–4273. PMID: 9766650
11. Raman V, Martensen SA, Reisman D, Evron E, OdenwaldWF, et al. (2000) Compromised HOXA5
function can limit p53 expression in human breast tumours. Nature 405: 974–978. PMID: 10879542
12. Rodriguez BA, Cheng AS, Yan PS, Potter D, Agosto-Perez FJ, et al. (2008) Epigenetic repression of
the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis 29: 1459–1465. doi:
10.1093/carcin/bgn115 PMID: 18499701
13. Seki H, Hayashida T, Jinno H, Hirose S, Sakata M, et al. (2012) HOXB9 expression promoting tumor
cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients. Ann
Surg Oncol 19: 1831–1840. doi: 10.1245/s10434-012-2295-5 PMID: 22396001
14. Plowright L, Harrington KJ, Pandha HS, Morgan R (2009) HOX transcription factors are potential thera-
peutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br J Cancer 100:
470–475. doi: 10.1038/sj.bjc.6604857 PMID: 19156136
15. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, et al. (2009) WNT/TCF signaling through LEF1
and HOXB9mediates lung adenocarcinoma metastasis. Cell 138: 51–62. doi: 10.1016/j.cell.2009.04.
030 PMID: 19576624
16. Tsai KW, Liao YL, Wu CW, Hu LY, Li SC, et al. (2012) Aberrant expression of miR-196a in gastric can-
cers and correlation with recurrence. Genes Chromosomes Cancer 51: 394–401. PMID: 22420029
17. Hassan N, Hamada J, Murai T, Seino A, Takahashi Y, et al. (2006) Aberrant expression of HOX genes
in oral dysplasia and squamous cell carcinoma tissues. Oncol Res 16: 217–224. PMID: 17294802
HOXB9 andmiR196a in HNSCC
PLOSONE | DOI:10.1371/journal.pone.0122285 April 10, 2015 16 / 19
18. Li Y, Zhang M, Chen H, Dong Z, Ganapathy V, et al. (2010) Ratio of miR-196s to HOXC8messenger
RNA correlates with breast cancer cell migration and metastasis. Cancer Res 70: 7894–7904. doi: 10.
1158/0008-5472.CAN-10-1675 PMID: 20736365
19. Asli NS, Kessel M (2010) Spatiotemporally restricted regulation of generic motor neuron programs by
miR-196-mediated repression of Hoxb8. Dev Biol 344: 857–868. doi: 10.1016/j.ydbio.2010.06.003
PMID: 20553899
20. Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, et al. (2009) MicroRNA-196a is a potential mark-
er of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esopha-
gus. Am J Pathol 174: 1940–1948. doi: 10.2353/ajpath.2009.080718 PMID: 19342367
21. McGlinn E, Yekta S, Mansfield JH, Soutschek J, Bartel DP, et al. (2009) In ovo application of antago-
miRs indicates a role for miR-196 in patterning the chick axial skeleton through Hox gene regulation.
Proc Natl Acad Sci U S A 106: 18610–18615. doi: 10.1073/pnas.0910374106 PMID: 19846767
22. Liu CJ, Tsai MM, Tu HF, Lui MT, Cheng HW, et al. (2012) miR-196a Overexpression and miR-196a2
Gene Polymorphism Are Prognostic Predictors of Oral Carcinomas. Ann Surg Oncol.
23. Yekta S, Shih IH, Bartel DP (2004) MicroRNA-directed cleavage of HOXB8mRNA. Science 304: 594–
596. PMID: 15105502
24. Braig S, Mueller DW, Rothhammer T, Bosserhoff AK (2010) MicroRNAmiR-196a is a central regulator
of HOX-B7 and BMP4 expression in malignant melanoma. Cell Mol Life Sci 67: 3535–3548. doi: 10.
1007/s00018-010-0394-7 PMID: 20480203
25. Liu XH, Lu KH, Wang KM, Sun M, Zhang EB, et al. (2012) MicroRNA-196a promotes non-small cell
lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer 12: 348. doi: 10.
1186/1471-2407-12-348 PMID: 22876840
26. Sun M, Liu XH, Li JH, Yang JS, Zhang EB, et al. (2012) MiR-196a is upregulated in gastric cancer and
promotes cell proliferation by downregulating p27(kip1). Mol Cancer Ther 11: 842–852. doi: 10.1158/
1535-7163.MCT-11-1015 PMID: 22343731
27. Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, et al. (2008) MicroRNA-196a targets annexin A1: a
microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 27: 6667–6678.
doi: 10.1038/onc.2008.256 PMID: 18663355
28. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, et al. (2009) Robust global micro-RNA profiling with for-
malin-fixed paraffin-embedded breast cancer tissues. Lab Invest 89: 597–606. doi: 10.1038/labinvest.
2009.12 PMID: 19290006
29. Mueller DW, Bosserhoff AK (2011) MicroRNAmiR-196a controls melanoma-associated genes by regu-
lating HOX-C8 expression. Int J Cancer 129: 1064–1074. doi: 10.1002/ijc.25768 PMID: 21077158
30. Severino P, Bruggemann H, Andreghetto FM, Camps C, Klingbeil Mde F, et al. (2013) MicroRNA ex-
pression profile in head and neck cancer: HOX-cluster embedded microRNA-196a and microRNA-10b
dysregulation implicated in cell proliferation. BMC Cancer 13: 533. doi: 10.1186/1471-2407-13-533
PMID: 24209638
31. Burns J, Baird M, Clark L, Burns P, Edington K, et al. (1993) Gene mutations and increased levels of
p53 protein in human squamous cell carcinomas and their cell lines. British Journal of Cancer 67:
1274–1284. PMID: 8390283
32. Burns JE, McFarlane R, Clark LJ, Mitchell R, Robertson G, et al. (1994) Maintenance of identical p53
mutations throughout progression of squamous cell carcinomas of the tongue. Eur J Cancer B Oral
Oncol 30B: 335–337. PMID: 7703803
33. Prime SS, Nixon SV, Crane IJ, Stone A, Matthews JB, et al. (1990) The behaviour of human oral squa-
mous cell carcinoma in cell culture. J Pathol 160: 259–269. PMID: 1692339
34. McGregor F, Muntoni A, Fleming J, Brown J, Felix DH, et al. (2002) Molecular changes associated with
oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine.
Cancer Res 62: 4757–4766. PMID: 12183435
35. McGregor F, Wagner E, Felix D, Soutar D, Parkinson K, et al. (1997) Inappropriate retinoic and receptor
β expression in oral dysplasias: correlation with acquisition of the immortal phenotype. Cancer research
57: 3886–3889. PMID: 9307265
36. Colley HE, Hearnden V, Jones AV, Weinreb PH, Violette SM, et al. (2011) Development of tissue-engi-
neered models of oral dysplasia and early invasive oral squamous cell carcinoma. Br J Cancer 105:
1582–1592. doi: 10.1038/bjc.2011.403 PMID: 21989184
37. Dickson MA, HahnWC, Ino Y, Ronfard V, Wu JY, et al. (2000) Human keratinocytes that express
hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet
retain normal growth and differentiation characteristics. Mol Cell Biol 20: 1436–1447. PMID: 10648628
38. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, et al. (1985) Measurement of protein using
bicinchoninic acid. Anal Biochem 150: 76–85. PMID: 3843705
HOXB9 andmiR196a in HNSCC
PLOSONE | DOI:10.1371/journal.pone.0122285 April 10, 2015 17 / 19
39. Neves JI, Begnami MD, Arias V, Santos GC (2005) Antigen retrieval methods and estrogen receptor
immunoexpression using 1D5 antibody: a comparative study. Int J Surg Pathol 13: 353–357. PMID:
16273191
40. Detre S, Saclani Jotti G, Dowsett M (1995) A "quickscore" method for immunohistochemical semiquan-
titation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48: 876–878. PMID:
7490328
41. Mao L, Ding J, Zha Y, Yang L, McCarthy BA, et al. (2011) HOXC9 links cell-cycle exit and neuronal dif-
ferentiation and is a prognostic marker in neuroblastoma. Cancer Res 71: 4314–4324. doi: 10.1158/
0008-5472.CAN-11-0051 PMID: 21507931
42. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, et al. (2002) Quantitative HOX expression in
chromosomally defined subsets of acute myelogenous leukemia. Leukemia 16: 186–195. PMID:
11840284
43. Nonn L, Vaishnav A, Gallagher L, Gann PH (2010) mRNA and micro-RNA expression analysis in laser-
capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials. Exp
Mol Pathol 88: 45–51. doi: 10.1016/j.yexmp.2009.10.005 PMID: 19874819
44. Chen Z, Jin Y, Yu D, Wang A, Mahjabeen I, et al. (2012) Down-regulation of the microRNA-99 family
members in head and neck squamous cell carcinoma. Oral Oncol 48: 686–691. doi: 10.1016/j.
oraloncology.2012.02.020 PMID: 22425712
45. Zhang H, Su YL, Yu H, Qian BY (2012) Meta-Analysis of the Association between Mir-196a-2 Polymor-
phism and Cancer Susceptibility. Cancer Biol Med 9: 63–72. doi: 10.3969/j.issn.2095-3941.2012.01.
012 PMID: 23691458
46. Tsai MM, Wang CS, Tsai CY, Chen CY, Chi HC, et al. (2014) MicroRNA-196a/-196b promote cell me-
tastasis via negative regulation of radixin in human gastric cancer. Cancer Lett 351: 222–231. doi: 10.
1016/j.canlet.2014.06.004 PMID: 24933454
47. Kanai M, Hamada J, Takada M, Asano T, Murakawa K, et al. (2010) Aberrant expressions of HOX
genes in colorectal and hepatocellular carcinomas. Oncol Rep 23: 843–851. PMID: 20127028
48. Sha S, Gu Y, Xu B, Hu H, Yang Y, et al. (2013) Decreased expression of HOXB9 is related to poor over-
all survival in patients with gastric carcinoma. Dig Liver Dis.
49. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, et al. (2004) Identification of a gene expres-
sion signature associated with recurrent disease in squamous cell carcinoma of the head and neck.
Cancer Res 64: 55–63. PMID: 14729608
50. Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, et al. (2013) Molecular subtypes in head and
neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS
One 8: e56823. doi: 10.1371/journal.pone.0056823 PMID: 23451093
51. Chiba N, Comaills V, Shiotani B, Takahashi F, Shimada T, et al. (2012) Homeobox B9 induces epitheli-
al-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses.
Proc Natl Acad Sci U S A 109: 2760–2765. doi: 10.1073/pnas.1018867108 PMID: 21930940
52. Sha L, Dong L, Lv L, Bai L, Ji X (2014) HOXB9 promotes epithelial-to-mesenchymal transition via trans-
forming growth factor-beta1 pathway in hepatocellular carcinoma cells. Clin Exp Med.
53. Nagel S, Burek C, Venturini L, Scherr M, Quentmeier H, et al. (2007) Comprehensive analysis of
homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9mediat-
ed via ERK5 signaling and BMI1. Blood 109: 3015–3023. PMID: 17148583
54. Danen-van Oorschot AA, Kuipers JE, Arentsen-Peters S, Schotte D, de Haas V, et al. (2012) Differen-
tially expressedmiRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.
Pediatr Blood Cancer 58: 715–721. doi: 10.1002/pbc.23279 PMID: 21818844
55. Mainguy G, Koster J, Woltering J, Jansen H, Durston A (2007) Extensive polycistronism and antisense
transcription in the mammalian Hox clusters. PLoS One 2: e356. PMID: 17406680
56. Cismasiu VB, Denes SA, Reilander H, Michel H, Szedlacsek SE (2004) The MAM (meprin/A5-protein/
PTPmu) domain is a homophilic binding site promoting the lateral dimerization of receptor-like protein-
tyrosine phosphatase mu. J Biol Chem 279: 26922–26931. PMID: 15084579
57. Diaz-Lopez A, Iniesta P, Moran A, Ortega P, Fernandez-Marcelo T, et al. (2010) Expression of Human
MDGA1 Increases Cell Motility and Cell-Cell Adhesion and Reduces Adhesion to Extracellular Matrix
Proteins in MDCK Cells. Cancer Microenviron 4: 23–32. doi: 10.1007/s12307-010-0055-2 PMID:
21505559
58. Zhang P, Becka S, Craig SE, Lodowski DT, Brady-Kalnay SM, et al. (2009) Cancer-derived mutations
in the fibronectin III repeats of PTPRT/PTPrho inhibit cell-cell aggregation. Cell Commun Adhes 16:
146–153. doi: 10.3109/15419061003653771 PMID: 20230342
HOXB9 andmiR196a in HNSCC
PLOSONE | DOI:10.1371/journal.pone.0122285 April 10, 2015 18 / 19
59. Yu J, Becka S, Zhang P, Zhang X, Brady-Kalnay SM, et al. (2008) Tumor-derived extracellular muta-
tions of PTPRT /PTPrho are defective in cell adhesion. Mol Cancer Res 6: 1106–1113. doi: 10.1158/
1541-7786.MCR-07-2123 PMID: 18644975
60. PanW (2002) A comparative review of statistical methods for discovering differentially expressed
genes in replicated microarray experiments. Bioinformatics 18: 546–554. PMID: 12016052
HOXB9 andmiR196a in HNSCC
PLOSONE | DOI:10.1371/journal.pone.0122285 April 10, 2015 19 / 19
